Project Details
Description
A phase III, double-blind, placebo-controlled study of Vemurafenib vs. Vemurafenib plus GDC-0973 in previously untreated BRAF v600 mutation positive patients with unresectable locally advances or metastatic melanoma
| Status | Finished |
|---|---|
| Effective start/end date | 10/30/12 → 12/31/15 |
Funding
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.